Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanadaBis CapitalTSXV:CANB PB Ratio is 0.27 as of Jul. 16, 2026, which is 92% below its 10-year median of 3.54. The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, CanadaBis Capital ranks better than 97.51% on this metric.
CanadaBis Capital Inc stock PB Ratio (=0.27) is close to 10-year low of 0.27.
The historical rank and industry rank for CanadaBis Capital's PB Ratio or its related term are showing as below:
TSXV:CANB'
s PB Ratio Range Over the Past 10 Years
Min: 0.27 Med: 3.54 Max: 10
Current: 0.27
During the past 10 years, CanadaBis Capital's highest PB Ratio was 10.00. The lowest was 0.27. And the median was 3.54.
TSXV:CANB's PB Ratio is ranked better than 97.51% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.955
vs TSXV:CANB: 0.27
During the past 12 months, CanadaBis Capital's average Book Value Per Share Growth Rate was -6.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 44.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 30.60% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of CanadaBis Capital was 59.80% per year. The lowest was -31.20% per year. And the median was 8.90% per year.
Back to Basics: PB Ratio
CanadaBis Capital (TSXV:CANB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CanadaBis Capital PB Ratio Related Terms
CanadaBis Capital PB Ratio Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs NPHC, BSPK, CPMD: PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's PB Ratio distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CanadaBis Capital (TSXV:CANB) has a PB Ratio of 0.27 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CanadaBis Capital and its competitors. This is 92% below median its historical median of 3.54. Over the past decade, CanadaBis Capital's PB Ratio has ranged from 0.27 to 10.00. According to the industry distribution chart, CanadaBis Capital ranks #23 out of 922 companies in the Drug Manufacturers industry, placing it in the top 2.5%.
Is CanadaBis Capital's PB Ratio too high?
CanadaBis Capital's current PB Ratio of 0.27 is 92% below median its 10-year median of 3.54. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 10.00. The Drug Manufacturers industry median PB Ratio is 1.96. CanadaBis Capital's value of 0.27 is 86.2% below this industry median. Based on the distribution chart, CanadaBis Capital ranks #23 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CanadaBis Capital's PB Ratio compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #23 out of 922 companies for PB Ratio. This places CanadaBis Capital in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.96. CanadaBis Capital's value of 0.27 is 86.2% below this benchmark. Historically, CanadaBis Capital's own PB Ratio has ranged from 0.27 to 10.00 over the past decade. While the company's 10-year median is 3.54 vs. the industry median of 1.96, CanadaBis Capital has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current PB Ratio of 0.27 is 86.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current PB Ratio is 0.27, which is 92% below median its own 10-year median of 3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current PB Ratio of 0.27. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current PB Ratio is 0.27, which is 92% below median its 10-year median of 3.54 and 86.2% below the Drug Manufacturers industry median of 1.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current PB Ratio is 0.27 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 
